Brendon Young, Deborah W Neklason, Kathleen Clark, Bing-Jian Feng, Megan B Keener, Thérèse M Tuohy, Austin Wood, Wendy C McKinnon, Marc S Greenblatt, Sean V Tavtigian
{"title":"Functional Characterization of a Genetic Variant in the 5' UTR of APC 1B Promoter in a Familial Adenomatous Polyposis Family.","authors":"Brendon Young, Deborah W Neklason, Kathleen Clark, Bing-Jian Feng, Megan B Keener, Thérèse M Tuohy, Austin Wood, Wendy C McKinnon, Marc S Greenblatt, Sean V Tavtigian","doi":"10.1002/ajmg.a.63992","DOIUrl":null,"url":null,"abstract":"<p><p>Pathogenic germline variants in the APC gene result in familial adenomatous polyposis (FAP) which can escalate into colon cancer. Standard clinical testing failed to identify pathogenic variants in a 4-generation FAP family. We identified and assessed co-segregation of a 5' untranslated region (UTR) variant, NM_001127511.3 (APC) c.-40G>A (GRCh37 chr5:112043375) that creates a potential out-of-frame AUG start codon. The segregation odds of pathogenicity for the APC c.-40G>A variant are 159:1. Translation initiation confidence values for all possible AUGs in the 5' UTR created by a single nucleotide substitution were calculated using PreTIS online tool. The -40G>A variant scored the highest possible confidence value. To test -40G>A as an initiating methionine, we created reporter constructs consisting of the entire 5' UTR and first 81 bases of APC driving luciferase. When the -40G>A variant was present, luciferase activity was decreased to 14%-25% of the wild-type construct. When the premature start codon created by the -40G>A variant was in-frame with luciferase, we observed luciferase activity from this de novo false start site. Combined, our evidence supports classification of APC c.-40G>A to likely pathogenic, presumably through squelching of the canonical AUG start codon. More importantly, it underlines the feasibility and importance of clinical laboratories to screen noncoding regions.</p>","PeriodicalId":7507,"journal":{"name":"American Journal of Medical Genetics Part A","volume":" ","pages":"e63992"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Medical Genetics Part A","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/ajmg.a.63992","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Pathogenic germline variants in the APC gene result in familial adenomatous polyposis (FAP) which can escalate into colon cancer. Standard clinical testing failed to identify pathogenic variants in a 4-generation FAP family. We identified and assessed co-segregation of a 5' untranslated region (UTR) variant, NM_001127511.3 (APC) c.-40G>A (GRCh37 chr5:112043375) that creates a potential out-of-frame AUG start codon. The segregation odds of pathogenicity for the APC c.-40G>A variant are 159:1. Translation initiation confidence values for all possible AUGs in the 5' UTR created by a single nucleotide substitution were calculated using PreTIS online tool. The -40G>A variant scored the highest possible confidence value. To test -40G>A as an initiating methionine, we created reporter constructs consisting of the entire 5' UTR and first 81 bases of APC driving luciferase. When the -40G>A variant was present, luciferase activity was decreased to 14%-25% of the wild-type construct. When the premature start codon created by the -40G>A variant was in-frame with luciferase, we observed luciferase activity from this de novo false start site. Combined, our evidence supports classification of APC c.-40G>A to likely pathogenic, presumably through squelching of the canonical AUG start codon. More importantly, it underlines the feasibility and importance of clinical laboratories to screen noncoding regions.
期刊介绍:
The American Journal of Medical Genetics - Part A (AJMG) gives you continuous coverage of all biological and medical aspects of genetic disorders and birth defects, as well as in-depth documentation of phenotype analysis within the current context of genotype/phenotype correlations. In addition to Part A , AJMG also publishes two other parts:
Part B: Neuropsychiatric Genetics , covering experimental and clinical investigations of the genetic mechanisms underlying neurologic and psychiatric disorders.
Part C: Seminars in Medical Genetics , guest-edited collections of thematic reviews of topical interest to the readership of AJMG .